We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -2.12 | -1.31% | 159.60 | 162.44 | 158.12 | 162.31 | 1,962,137 | 16:46:34 |
From May 2022 to May 2024
By Colin Kellaher
AbbVie Inc. on Wednesday said the U.S. Food and Drug Administration has turned away its proposed ABBV-951 treatment of motor fluctuations in adults with advanced Parkinson's disease, requesting more information about the pump used to deliver the drug.
The North Chicago, Ill., biopharmaceutical company said the FDA issued a complete response letter, indicating the agency wouldn't approve the application in its current form.
ABBV-951 is an investigational combination of carbidopa and levodopa, prodrugs commonly used to treat the neurodegenerative movement disorder Parkinson's, delivered by a subcutaneous pump.
AbbVie, which filed for FDA approval of ABBV-951 last May, said the FDA didn't request any additional efficacy or safety trials related to the drug, adding that it plans to resubmit its application as soon as possible.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 22, 2023 09:29 ET (13:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
